Not Yet Recruiting

NCT Number: NCT06973382

Effects of Pulmonary Rehabilitation on Quality of Life and Health in Pulmonary Arterial Hypertension Patients

Pulmonary hypertension (PH) is a major global health concern, affecting approximately 1% of the world's population. With global aging and increased life expectancy, its incidence continues to rise. PH is a progressive and disabling disease, with studies showing its progression correlates with worsening symptoms and increased mortality. Even with targeted medications, the prognosis remains poor across PH subtypes, with PAH patients showing only a 49% 7-year survival rate. The 2022 ESC/ERS guidelines emphasize that PH management requires a comprehensive, multidisciplinary approach. Beyond pharmacological and surgical treatments, rehabilitation has demonstrated benefits in improving exercise capacity, quality of life, functional class, and peak oxygen consumption. However, research on specific and effective comprehensive pulmonary rehabilitation programs remains lacking.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

PAH CTEPH

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Confirmed PH Diagnosis:

Right heart catheterization-confirmed pulmonary hypertension

Meets 2022 ESC/ERS Guidelines diagnostic criteria for:

Group 1 (PAH) or
Group 4 (CTEPH/other pulmonary artery obstructions)

Stabilized Treatment Status:

Group 1 (PAH): Received ≥3 months of targeted drug therapy

Group 4 (CTEPH): Completed ≥6 sessions of BPA* or reached therapeutic endpoint

Functional Capacity:

WHO Functional Class I-III

Age: ≥18 years

Consent: Willing to provide written informed consent -

Exclusion criteria

Physical Limitations:

Unable to perform pulmonary rehabilitation exercises due to disability or congenital malformations

Cardiopulmonary Testing Contraindications:

Medically unfit to complete CPET (cardiopulmonary exercise testing) after evaluation

Poor Compliance:

History of non-adherence making protocol completion unlikely

Life Expectancy:

Prognosis ≤1 year

Treatment and study plan

Comprehensive Pulmonary Rehabilitation Program

Behavioral

Combined Aerobic + Resistance Training Program Mode: Cycle ergometry (stationary bicycle) Frequency: 3-5 sessions per week Program Duration: 12 weeks

Session Structure:

5-minute warm-up
Continuous or interval training (15-30 minutes)
5-minute cool-downesistance Exercise Component

Mode: Dumbbell exercises + cycle ergometry

Frequency: 3 sessions per week

Program Duration: 12 weeks

Session Structure:

5-minute warm-up
Training session (10-20 minutes)
5-minute cool-down

Standard Pulmonary Rehabilitation

Behavioral

xercise Components:

Aerobic Exercise

Mode: Walking or jogging

Resistance Exercise

Mode: Elastic bands or dumbbells

Training Parameters:

Session Duration: ≥35 minutes (combined aerobic + resistance)

Frequency: 3-5 sessions per week

Program Duration: 12 weeks

Primary outcomes

6MWD

Time frame: 12week

Sponsors and collaborators

Lead sponsor

Beijing Chao Yang Hospital

Other

Collaborators

Beijing Municipal Health Commission

Registry information

Official study title

Intervention Study of a Comprehensive Pulmonary Rehabilitation Program on Quality of Life and Prognosis in Patients With Pulmonary Arterial Hypertension

Acronym: EPRQoL-PAH

Important dates

Study start: 2025
Primary completion: 2027
Study completion: 2027
First posted: May 15, 2025
Registry last updated: May 15, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting